The viral puzzle of why humans are susceptible to hepatitis B virus, but monkeys are not!
Peer-Reviewed Publication
Updates every hour. Last Updated: 6-May-2025 13:09 ET (6-May-2025 17:09 GMT/UTC)
Hepatitis B virus (HBV) has a narrow host range, mainly infecting hominoids. A new study led by researchers from Japan reveals the structural differences in the liver cell receptor (NTCP) between humans and monkeys, explaining why HBV infects humans but not monkeys. This marks a significant medical breakthrough, by identifying new molecular targets for anti-HBV drug development for treating hepatitis B, a disease that places a tremendous burden on the global economy.
In a first-of-its-kind breakthrough, a team of UBC Okanagan researchers has developed an artificial adhesion system that closely mimics natural biological interactions.
Dr. Isaac Li and his team in the Irving K. Barber Faculty of Science study biophysics at the single-molecule and single-cell levels. Their research focuses on understanding how cells physically interact with each other and their environment, with the ultimate goal of developing innovative tools for disease diagnosis and therapy.
Ketone bodies are not just about energy. These metabolites are powerful signaling molecules that have profound effects on the proteome and protein quality control in the brain. Publishing in Cell Chemical Biology Buck Institute scientists, working in mouse models of Alzheimer’s disease and aging, and in the nematode C. elegans, reveal the ketone body β-hydroxybutyrate interacts directly with misfolded proteins, altering their solubility and structure so they can be cleared from the brain through the process of autophagy. The work hints at a tantalizing possibility – ketone bodies as a global treatment to restore the integrity of the proteome, addressing one of the key hallmarks of aging.